Asset

Cetuximab

Erasca Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (2)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT04670679phase1active_not_recruiting2020-12-152026-02-01Erasca, Inc.A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
NCT05039177phase1_2completed2021-09-202025-08-15Erasca, Inc.A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)